OpenAI says China's Zhipu AI gaining ground amid Beijing's global AI push
(Reuters) -OpenAI said on Wednesday its analysts have seen notable progress by Chinese start-up Zhipu AI in securing government contracts across several regions, signaling China's growing momentum in pursuing global AI leadership.
Zhipu AI, which is backed by the Chinese Communist Party, aims to "lock Chinese systems and standards into emerging markets before U.S. or European rivals can, while showcasing a 'responsible, transparent and audit-ready' Chinese AI alternative," the ChatGPT maker said in its post.
The company provides AI solutions — including sovereign large language model infrastructure and private hardware in partnership with Huawei — to governments and state-owned enterprises in Malaysia, Singapore, the UAE, Saudi Arabia and Kenya.
The initiative forms part of China's broader effort to build a self-sufficient, globally competitive AI ecosystem that rivals the United States while reducing reliance on American technology.
Zhipu AI, which did not immediately respond to a request for comment, is supported by more than $1.4 billion in state investment and maintains strong ties with the Chinese government and state-owned entities, according to OpenAI.
In January, the company was added to the U.S. Commerce Department's export control entity list, barring it from procuring U.S. components.
Zhipu AI has been positioning itself among China's leading AI firms alongside DeepSeek, Moonshot AI, and Minimax, as well as tech giants ByteDance and Alibaba.
OpenAI has also built partnerships and attracted investment across the Middle East and Asia. Its "OpenAI for Countries" initiative helps interested governments develop "sovereign AI capability" in coordination with the U.S. government.
The report comes as the U.S. and China engage in intense competition in the rapidly evolving AI landscape, with both nations vying for technological dominance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Analog Devices' (NASDAQ:ADI) 16% CAGR outpaced the company's earnings growth over the same five-year period
Passive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, the Analog Devices, Inc. (NASDAQ:ADI) share price is 95% higher than it was five years ago, which is more than the market average. Zooming in, the stock is up just 3.8% in the last year. On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Analog Devices achieved compound earnings per share (EPS) growth of 4.2% per year. This EPS growth is slower than the share price growth of 14% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. This optimism is visible in its fairly high P/E ratio of 64.21. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). Dive deeper into Analog Devices' key metrics by checking this interactive graph of Analog Devices's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Analog Devices, it has a TSR of 114% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Analog Devices shareholders gained a total return of 5.6% during the year. Unfortunately this falls short of the market return. On the bright side, the longer term returns (running at about 16% a year, over half a decade) look better. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. It's always interesting to track share price performance over the longer term. But to understand Analog Devices better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for Analog Devices you should be aware of. But note: Analog Devices may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
an hour ago
- CNBC
China's suppressed crypto demand is spilling over into these stocks
China essentially banned cryptocurrencies years ago. Now that pent-up demand is finding an outlet in Hong Kong markets as local regulators eye the potential of stablecoins. Hong Kong-traded shares of Guotai Junan International nearly tripled in price Wednesday after becoming the first mainland Chinese-backed securities brokerage to obtain a license for virtual currency trading in Hong Kong . So many mainland-based investors bought the Hong Kong-listed stock that Guotai's total trading value ranked first on the exchange on Wednesday and Thursday, exceeding that of Alibaba, according to Wind Information. Guotai held onto second place on Friday, ceding the top trading spot to Xiaomi after its electric car launch Thursday night, the data showed. As a special administrative region of China, Hong Kong operates under different financial regulations and allows bitcoin trading. In late May, the region passed a stablecoin bill to formalize the process for financial companies to issue and manage virtual assets, primarily those that reference government-issued, or fiat, currencies. "We believe China's newfound interest in stablecoins is driven by concerns that legislation of U.S. stablecoins could extend dollar dominance," Morgan Stanley's Chief China Economist Robin Xing and a team said in a June 19 report. The People's Bank of China "is exploring HK as a sandbox for future payment alternatives," the firm said. While the analysts pointed out that Beijing has banned crypto transactions in mainland China since 2021 , PBOC Governor Pan Gongsheng's high-profile speech in mid-June "signals a pivot." Pan highlighted stablecoins and also noted how digital technologies have exposed weaknesses in traditional payment systems, the Morgan Stanley analysts pointed out. A growing trend among companies Other Chinese companies are jumping onto the trend. Hong Kong-listed financial services firm China Renaissance announced Thursday it plans to spend $100 million over the next two years to invest in cryptocurrency assets and to develop its business in the related Web3.0 realm. On the same day, the company also announced that Frank Fu, a former CEO of crypto exchange Huobi Americas, would join China Renaissance as an independent non-executive director . China Renaissance, also known as CR Holdings, saw its shares gain 20% last week. In the mainland, where stock trading is subject to more price restrictions, Shanghai-listed TF Securities saw gains of nearly 29% last week after it confirmed to investors Friday its wholly-owned subsidiary, TF International, also obtained a license in Hong Kong for virtual assets trading. TF Securities and popular financial information and brokerage company Eastmoney saw the largest turnover by share volume and price last week on the mainland exchanges, according to Wind data, although Eastmoney did not share any virtual assets-related business updates. Its stock climbed by about 11% in the last week. Watch for the drivers behind shares' recent surge The leap in Guotai shares over the past week reflects the market's positive expectations for stablecoin business, Li Dongfang, a Beijing-based finance blogger, said in Chinese, translated by CNBC. But the stock price surge is due more to investors pursuing emerging themes and following first-mover advantage, rather than a reflection of new business growth, Li said. He expects more brokerages to also get similar approvals for virtual asset business, and not see such large fluctuations in stock prices. Part of Beijing's impetus for banning crypto trading was an effort to control financial risks. Speculation takes on a different form with a population of 1.4 billion people. However, the macro trend is clear, if not accelerating. The New York-founded cryptocurrency conference Consensus expanded to Hong Kong this year with its first event in the region in February. Another Consensus event is planned for Hong Kong next year. Recent Chinese business news reports have also scrutinized the potential for stablecoins in Chinese sales of goods overseas via online platforms. They have also highlighted how a unit of Chinese e-commerce company along with Standard Chartered, are among those officially participating in Hong Kong's stablecoin project. "For China, ignoring this trend risks being left behind in the digital infrastructure race – especially as stablecoins increasingly function as bypass mechanisms to traditional banking networks," the Morgan Stanley analysts said.
Yahoo
an hour ago
- Yahoo
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its 'Buy' rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist's move followed Eli Lilly's presentation at the American Diabetes Association (ADA) 85th Annual Meeting. Pixabay/Public Domain The rating pertains to Eli Lilly's oral diabetes drug, orforglipron (OFG), evaluated in the Phase 3 ACHIEVE-1 study for Type 2 diabetes treatment. The ACHIEVE-1 study results were presented at the ADA conference, showcasing orforglipron's efficacy and safety profile. The trial demonstrated statistically significant reductions in A1C (a long-term blood sugar metric) and body weight compared to placebo, with efficacy increasing at higher doses. Truist's analysis was informed by attending the orforglipron presentation, gathering feedback from KOLs at the ADA conference, and participating in Eli Lilly's investor event, where management provided clarity to alleviate safety concerns. The firm noted that longer-term data are required to further strengthen orforglipron's safety profile, particularly for chronic use in diabetes and potential obesity indications. Eli Lilly and Company (NYSE:LLY) is an American global biopharmaceutical company. The company discovers, develops, and markets prescription medicines for diabetes, obesity, cancer, immunological disorders, and neurological diseases. Its key products include Mounjaro, Zepbound, Trulicity, Verzenio, Taltz, and Jardiance. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
